• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

    7/17/24 8:00:00 AM ET
    $MDXG
    $SAVA
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email
    • Rick Barry appointed Executive Chairman of the Board
    • Remi Barbier resigns as President and CEO and from the Board of Directors
    • Cassava initiates search for a new CEO

    AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO.

    Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a non-executive capacity, without duties or responsibilities.

    Lindsay Burns, Ph.D., SVP, Neuroscience, at Cassava is also leaving the employ of the Company. Cassava and Dr. Burns have agreed that she step down from her role with the Company, effective immediately. Following her separation from the Company and for a one-year period, Dr. Burns will furnish consulting services as, and to the extent, reasonably requested by Cassava for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Company's products. Cassava may, in its sole discretion, extend the term of the consulting agreement for up to an additional year.

    Mr. Barry has served as a director of Cassava since June 2021. Since June 2015, Mr. Barry has also served as Director of Sarepta Therapeutics, Inc., (NASDAQ:SRPT) and from June 2019 through October 2020, he served as a director of MiMedx Group Inc. (NASDAQ:MDXG). He has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. He holds a Bachelor of Arts from Pennsylvania State University.

    "As a public company, and one dedicated to developing a drug for Alzheimer's disease, we hold ourselves to the highest standards," Mr. Barry said. "While our priority remains the development of a potentially effective treatment for Alzheimer's disease, the Board has a steadfast commitment to doing so with transparency, accountability, and highest ethical business practices." Among the actions the company is taking are:

    New Leadership: The Board has appointed Rick Barry as Executive Chairman and is in the process of identifying a new CEO who has relevant industry and corporate governance experience. With the identification of a new CEO, the Board plans to separate the Chairman and CEO roles.

    Single-minded Commitment to Scientific Rigor and Honest Transparency: Our sole mission at this time is to determine whether simufilam is an effective, revolutionary treatment for Alzheimer's disease.  The Company plans to achieve that mission through a single-minded commitment to scientific rigor and honest transparency with patients, government agencies and investors. All study results will be posted timely and accurately to clinicaltrials.gov.

    Rigorous Clinical Trials:  The ongoing Phase 3 trials are being run according to FDA and industry standards that ensure the integrity of all reported results.

    • Under the Phase 3 protocols reviewed by the FDA, no individual within the Company knows or will know which subjects are receiving a drug or placebo.  Blinding information is and will be held exclusively by a small group of professionals at our CRO, Premier Research.  Likewise, no individual within the Company has access to sub-study results and other information that might be used to infer which patients are on placebo.  All such data is transmitted directly to Premier Research.

    • Statistical analyses for the Phase 3 trials will be conducted by professional biostatisticians at Pentara Corporation. Trial results are transmitted directly to these biostatisticians by our CRO, independent of any involvement by the Company.

    Transparency in Communications and Reporting: Cassava remains committed to fostering open communication and engagement with its stakeholders. The Company and its management will communicate regularly and clearly to our constituencies, beginning with a renewal of quarterly analyst calls and will be reasonably available to journalists. Cassava is reviewing its disclosure practices to ensure it is providing stakeholders with clear and comprehensive information. Regular dialogues with shareholders, employees, customers, regulators, and the broader community will continue to inform and shape the company's governance practices.

    "We have an extraordinary board of directors," Mr. Barry said, "that remains focused on continuing to strengthen the company's corporate governance framework and on enhancing its commitment to responsible and transparent stakeholder engagement."  

    Mr. Barry said that in addition to the leadership changes, the Board has added Pierre Gravier as the Chair of the Audit Committee and Robert Anderson, Jr. as the Chair of the Nominating and Governance Committee.

    Cautionary Note Regarding Forward-Looking Statements:

    This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to statements regarding: the design, scope, conduct, continuation, completion, intended purpose, or future results of our on-going Phase 3 clinical trials of simufilam in patients with Alzheimer's disease; the timing of anticipated milestones; the safety or efficacy of simufilam in people with Alzheimer's disease dementia; potential benefits, if any, of our product candidates, and the implementation of governance enhancements. These statements may be identified by words such as "anticipate," "believe," "could," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," and other words and terms of similar meaning.

    Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, the ability to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates; our current expectations regarding timing of clinical data for our Phase 3 clinical trials; any expected clinical results of Phase 3 clinical trials; potential benefits, if any, of our product candidates and those described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent reports filed with the SEC. Clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this news release.

    All our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates are approved or available for sale anywhere in the world.

    For more information:

    Sitrick And Company

    1-800-550-7521

    [email protected]

    Seth Lubove: [email protected]

    NY:

    Rich Wilner: [email protected] 800-699-1481



    Primary Logo

    Get the next $MDXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDXG
    $SAVA
    $SRPT

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    5/8/2025$50.00Outperform → In-line
    Evercore ISI
    Sarepta Therapeutics Inc.
    $SRPT
    4/11/2025$115.00Overweight
    Wells Fargo
    Sarepta Therapeutics Inc.
    $SRPT
    4/2/2025$75.00Sell → Neutral
    H.C. Wainwright
    Sarepta Therapeutics Inc.
    $SRPT
    3/31/2025$161.00 → $87.00Outperform → Sector Perform
    RBC Capital Mkts
    Sarepta Therapeutics Inc.
    $SRPT
    2/11/2025$136.00Hold
    Deutsche Bank
    Sarepta Therapeutics Inc.
    $SRPT
    11/27/2024$205.00 → $202.00Buy
    Needham
    Cassava Sciences Inc.
    $SAVA
    11/26/2024Buy → Neutral
    H.C. Wainwright
    Sarepta Therapeutics Inc.
    $SRPT
    11/25/2024$80.00Sell
    H.C. Wainwright
    More analyst ratings

    $MDXG
    $SAVA
    $SRPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sarepta Therapeutics downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Sarepta Therapeutics from Outperform to In-line and set a new price target of $50.00

      5/8/25 8:27:43 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Sarepta Therapeutics with a new price target

      Wells Fargo initiated coverage of Sarepta Therapeutics with a rating of Overweight and set a new price target of $115.00

      4/11/25 9:10:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Sarepta Therapeutics from Sell to Neutral and set a new price target of $75.00

      4/2/25 8:22:16 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    $SAVA
    $SRPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

      As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bor

      5/1/25 7:30:00 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

      AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Company also appointed Jack Moore, PhD, as Senior Vice President, Clinical Development, reporting to Rick Barry, Chief Executive Officer. "The entire Cassava team is grateful for Jim's service as our Chief Medical Officer. He is retiring after a notable care

      4/21/25 4:30:00 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

      Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava's commercial readiness strategy as the Company prepares for first Phase 3 topline data readout before year end 2024 AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. As a member of the Company's executive leadership team, Ms. Nassif will report to Richard "Rick" Barry, President and Chief Executive of Cas

      11/18/24 8:30:00 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    $SAVA
    $SRPT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cassava Sciences Inc.

      10-Q - CASSAVA SCIENCES INC (0001069530) (Filer)

      5/8/25 4:01:39 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

      5/8/25 8:15:10 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Sarepta Therapeutics Inc.

      10-Q - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      5/6/25 4:01:26 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    $SAVA
    $SRPT
    Financials

    Live finance-specific insights

    See more
    • Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

      Net product revenues for the first quarter 2025 totaled $611.5 million, a 70% increase over the same quarter of the prior year ELEVIDYS net product revenue for the first quarter totaled $375.0 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $4.0 million Revised 2025 total net product revenues guidance to $2.3 to $2.6 billion Meaningfully advanced multiple clinical candidates in limb-girdle muscular dystrophy portfolio Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025. "In the first quarter, we achieved net product revenue of $611.5 mi

      5/6/25 4:05:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces First Quarter 2025 Operating and Financial Results

      Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid first quarter 2025 results include total

      4/30/25 4:01:00 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

      Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the Nasdaq Global Market closes on Tuesday, May 6, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone

      4/22/25 8:30:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    $SAVA
    $SRPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

      7/12/24 4:40:36 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

      For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

      6/20/24 5:24:42 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

      6/5/24 4:41:31 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    $SAVA
    $SRPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

      SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      11/13/24 10:27:59 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

      SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

      11/12/24 4:04:33 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MiMedx Group Inc

      SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

      11/7/24 10:25:58 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    $SAVA
    $SRPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      5/5/25 10:06:51 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      8/20/24 8:00:04 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      11/22/23 5:01:18 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    $SAVA
    $SRPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

      Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the BofA Securities Health Care Conference at the Encore Hotel in Las Vegas, Nev. on Wednesday, May 14, 2025 at 8:40 a.m. P.T./11:40 a.m. E.T. The presentations will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be

      5/8/25 4:30:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Reports Q1 2025 Financials Results, Provides Business Update

      License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "Cassava has made significant progress this year in leveraging our science to expand our portfolio. Our license with Yale University for inte

      5/8/25 8:00:00 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

      Net product revenues for the first quarter 2025 totaled $611.5 million, a 70% increase over the same quarter of the prior year ELEVIDYS net product revenue for the first quarter totaled $375.0 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $4.0 million Revised 2025 total net product revenues guidance to $2.3 to $2.6 billion Meaningfully advanced multiple clinical candidates in limb-girdle muscular dystrophy portfolio Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025. "In the first quarter, we achieved net product revenue of $611.5 mi

      5/6/25 4:05:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    $SAVA
    $SRPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      5/5/25 10:06:51 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 8,876 shares, decreasing direct ownership by 2% to 422,426 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      4/25/25 6:03:03 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Schoen Eric

      4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

      4/21/25 4:51:38 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care